A study of Antroquinonol in combination with nab-paclitaxel plus gemcitabine in the treatment of first line metastasis pancreatic cancer

Trial Profile

A study of Antroquinonol in combination with nab-paclitaxel plus gemcitabine in the treatment of first line metastasis pancreatic cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Antroquinonol (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2017 New trial record
    • 19 Jul 2017 According to a Golden Biotechnology Corporation media release, the U.S. FDA approved the IND and execution of the safety and efficacy trial of Antroquinonol combined with nab-paclitaxel plus gemcitabine in first line metastasis pancreatic cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top